CAD, Lipid Sub-fractionation and Lp(a) with Dr Paul Thompson
Mar 8, 2022
auto_awesome
In this engaging discussion, Dr. Paul Thompson, a leading expert in cardiology and sports medicine, dives deep into the nuances of coronary artery disease and lipid management. He breaks down the critical role of lipoprotein A as a cardiovascular risk factor, especially for athletes. The conversation highlights the need for comprehensive care in handling elevated lipoprotein A and LDL cholesterol effectively. Additionally, Dr. Thompson touches on innovative anticoagulation strategies and the latest research impacting heart disease management.
Lipoprotein A is a crucial risk factor for cardiovascular disease that exists independently of LDL cholesterol, affecting treatment strategies.
ApoB measurement is vital for assessing cardiovascular risk, providing a clearer understanding of atherogenic particle presence compared to traditional lipid panels.
Deep dives
The Impact of Lipoprotein A on Cardiovascular Health
Lipoprotein A is identified as a significant risk factor for cardiovascular disease, independent of LDL cholesterol levels. This component resembles plasminogen, which may interfere with clot resolution and contribute to vascular inflammation. Elevated levels of lipoprotein A are found in about 20% of the population and can complicate cholesterol plaque composition, potentially leading to adverse coronary events. Ongoing research, including industry studies, aims to find effective treatments to lower lipoprotein A levels and assess its impact on patient survival.
ApoB as a Key Indicator for Cardiovascular Risk
ApoB serves as an essential measurement for assessing cardiovascular risk, as it indicates the number of atherogenic particles in the bloodstream. Elevated levels of ApoB correlate with a higher likelihood of atherosclerosis, and this can provide a clearer understanding of a patient's risk compared to traditional lipid panels. Monitoring ApoB levels allows healthcare providers to determine treatment strategies for patients, especially when combined with other risk factors. This approach emphasizes the importance of understanding particle number rather than just their size or density.
Aggressive Management of Risk Factors
The focus in treatment should center on managing risk rather than merely targeting specific risk factors like elevated lipoprotein A. For patients with established heart disease, reducing LDL cholesterol to the lowest possible level is crucial, even under aggressive treatment regimens including statins and PCSK9 inhibitors. Individualized care is paramount; understanding patient concerns and history can guide decisions on interventions and screenings, such as measuring lipoprotein A levels. This results in careful management that balances treatment efficacy with the patient's overall health and financial considerations.
Our inaugural podcast is a discussion between Dr. Paul Thompson, Chief of Cardiology, Emeritus, at Hartford Hospital and Professor of Medicine, Emeritus, at University of Connecticut and Dr. Thomas Nero, Director of Cardiovascular Research at CAFC about coronary artery disease, lipid sub-fractionation and the role of lipoprotein a, aka Lp(a).
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode